AI Quick Summary

👋 Welcome Tubulis GmbH at Biopôle I Site of Switzerland Innovation Park West EPFL!With a bold vision to expand the therapeutic potential of antibody-drug conjugates (ADCs), Tubulis is redefining targeted cancer therapy through uniquely matched ADCs with superior biophysical properties.🧬 Backed by proprietary platform technologies, their next-generation ADCs have shown durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models. Now, their lead candidates – TUB-040 (targeting NaPi2b) and TUB-030 (targeting 5T4) – are advancing through the clinic in high-need solid tumor indications.Tubulis continues to innovate across every aspect of ADC design, with a pipeline that serves not only their own programmes but also strategic partners. Their goal is to unlock a new era of precision oncology for patients who need it most.🔎 Learn more about their pioneering approach: https://www.biopole.ch/company/tubulis/

Post Metadata

• Author: Switzerland Innovation Digital
• Published Date: 7/16/2025 9:51:13 AM
• Modified Date: 7/16/2025 9:51:13 AM

Post Description

👋 Welcome Tubulis GmbH at Biopôle I Site of Switzerland Innovation Park West EPFL!

With a bold vision to expand the therapeutic potential of antibody-drug conjugates (ADCs), Tubulis is redefining targeted cancer therapy through uniquely matched ADCs with superior biophysical properties.

🧬 Backed by proprietary platform technologies, their next-generation ADCs have shown durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models. Now, their lead candidates – TUB-040 (targeting NaPi2b) and TUB-030 (targeting 5T4) – are advancing through the clinic in high-need solid tumor indications.

Tubulis continues to innovate across every aspect of ADC design, with a pipeline that serves not only their own programmes but also strategic partners. Their goal is to unlock a new era of precision oncology for patients who need it most.

🔎 Learn more about their pioneering approach: https://www.biopole.ch/company/tubulis/